Two-year results from the PARTNER 3 trial show transcatheter aortic valve replacement (TAVR) with Edwards Lifesciences Corp. balloon-expandable Sapien 3 system is a safe and effective alternative to open surgical valve replacement in low-risk patients.
The low-risk cohort in PARTNER 3 randomized 1,000 patients with severe stenosis in a tricuspid aortic valve and a